Patents by Inventor Eliot H. Ohlstein

Eliot H. Ohlstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating isolated systolic hypertension
    Publication number: 20030045561
    Abstract: This invention relates to the use of eprosartan to treat isolated systolic hypertension.
    Type: Application
    Filed: September 19, 2002
    Publication date: March 6, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: David P. Brooks, Giora Z. Feuerstein, Eliot H. Ohlstein, Robert R. Ruffolo
  • Method of treating isolated systolic hypertension
    Publication number: 20020040045
    Abstract: This invention relates to the use of eprosartan to treat isolated systolic hypertension.
    Type: Application
    Filed: October 24, 2001
    Publication date: April 4, 2002
    Applicant: SmithKline Beecham Corporation
    Inventors: David P. Brooks, Giora Z. Feuerstein, Eliot H. Ohlstein, Robert R. Ruffolo
  • Method of treating isolated systolic hypertension
    Publication number: 20010005723
    Abstract: This invention relates to the use of eprosartan to treat isolated systolic hypertension.
    Type: Application
    Filed: February 6, 2001
    Publication date: June 28, 2001
    Applicant: SmithKline Beecham Corporation
    Inventors: David P. Brooks, Giora Z. Feuerstein, Eliot H. Ohlstein, Robert R. Ruffolo
  • Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
    Patent number: 5643939
    Abstract: A new use of, and method of treatment using, a compound selected from the group consisting essentially of compounds of Formula I: ##STR1## wherein: R.sub.1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;R.sub.2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;R.sub.3 is hydrogen or lower alkyl of up to 6 carbon atoms;R.sub.4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R.sub.4 together with R.sub.5 can represent --CH.sub.2 --O--;X is a valency bond, --CH.sub.2, oxygen or sulfur;Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl;R.sub.5 and R.sub.6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a --CONH.sub.
    Type: Grant
    Filed: February 16, 1994
    Date of Patent: July 1, 1997
    Assignee: Boehringer Mannheim Pharmaceutical Corporation-SmithKline Beecham Corporation
    Inventor: Eliot H. Ohlstein
  • Treatment of athereosclerosis using, carbazolyl-(4)-oxypropanolamine compounds
    Patent number: 5453436
    Abstract: A new use of, and method of treatment of atherosclerosis using, a compound selected from the group consisting essentially of compounds of Formula I: ##STR1## wherein: R.sub.1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;R.sub.2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;R.sub.3 is hydrogen or lower alkyl of up to 6 carbon atoms;R.sub.4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R.sub.4 together with R.sub.5 can represent --CH.sub.2 --O--;X is a valency bond, --CH.sub.2, oxygen or sulfur;Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl;R.sub.5 and R.sub.6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a --CONH.sub.
    Type: Grant
    Filed: March 17, 1994
    Date of Patent: September 26, 1995
    Assignees: Boehringer Mannheim Pharmaceutical Corporation, SmithKline Beecham Corp.
    Inventor: Eliot H. Ohlstein
  • Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
    Patent number: 5393772
    Abstract: The present invention provides a new medical use of the hydroxycarbazole compounds of Formula (I), preferably the hydroxylated metabolites of 1-(carbazol-4-yloxy-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol)(carve dilol), for inhibiting the migration and proliferation of smooth muscle cells. In particular, the present invention provides a new use for the hydroxycarbazole compounds of Formula (I) for prevention of restenosis following percutaneous transluminal coronary angioplasty (PTCA), suppression of the progression of vascular hypertrophy associated with hypertension, and prevention of development of atherosclerosis. ##STR1## wherein: R.sub.1 -R.sub.9 are independently --H or --OH, with the proviso that a at least one of R.sub.1 -R.sub.9 is OH.
    Type: Grant
    Filed: November 24, 1993
    Date of Patent: February 28, 1995
    Assignees: Boehringer Mannheim Pharmaceuticals Corporation, SmithKline Beecham Corporation Limited Prtnrshp No. 1
    Inventors: Tian-Li Yue, Eliot H. Ohlstein, Giora Z. Feuerstein
  • Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
    Patent number: 5308862
    Abstract: A new use of, and method of treatment using, a compound selected from the group consisting essentially of compounds of Formula I: ##STR1## wherein: R.sub.1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;R.sub.2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;R.sub.3 is hydrogen or lower alkyl of up to 6 carbon atoms;R.sub.4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R.sub.4 together with R.sub.5 can represent --CH.sub.2 --O--;X is a valency bond, --CH.sub.2, oxygen or sulfur;Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl;R.sub.5 and R.sub.6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a --CONH.sub.
    Type: Grant
    Filed: March 5, 1993
    Date of Patent: May 3, 1994
    Assignee: Boehringer Mannheim Pharmaceuticals Corporation - SmithKline Beecham Corp., Ltd. Partnership No. 1
    Inventor: Eliot H. Ohlstein
  • Dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4935438
    Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals.
    Type: Grant
    Filed: December 29, 1987
    Date of Patent: June 19, 1990
    Assignee: SmithKline Beckman Corporation
    Inventors: Lawrence I. Kruse, Stephen T. Ross, Eliot H. Ohlstein
  • Intermediate to dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4912226
    Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
    Type: Grant
    Filed: September 15, 1989
    Date of Patent: March 27, 1990
    Assignee: SmithKline Beckman Corporation
    Inventors: Lawrence I. Kruse, Stephen T. Ross, Eliot H. Ohlstein
  • 2-(aminoalkylthio)imidazoles as dopamine-.beta.-hydroxylase inhibitors
    Patent number: 4882348
    Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mannals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
    Type: Grant
    Filed: December 29, 1987
    Date of Patent: November 21, 1989
    Assignee: SmithKline Beckman Corporation
    Inventors: Lawrence I. Kruse, Stephen T. Ross, Eliot H. Ohlstein